Export financials
QIAGEN N.V. (QGEN)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

QIAGEN N.V. Financial Statements 2025-2011 | QGEN
Annual Financial Statements QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 8.52 B | 10 B | 9.8 B | 11.3 B | 11.4 B | 8.14 B | 8.71 B | 7.69 B | 6.44 B | 5.3 B | 5.33 B | 5.2 B | 4.98 B | 3.83 B |
Shares |
217 M | 223 M | 228 M | 228 M | 228 M | 228 M | 227 M | 227 M | 228 M | 226 M | 224 M | 223 M | 225 M | 226 M | 226 M |
Historical Prices |
- | 38.3 | 44 | 43.1 | 49.7 | 50 | 35.9 | 38.4 | 33.7 | 27.4 | 21.1 | 25.3 | 22.2 | 21.4 | 15.3 |
Net Income |
425 M | 83.6 M | 341 M | 423 M | 513 M | 359 M | -41.5 M | 190 M | 40.4 M | 80.4 M | 127 M | 117 M | 69.1 M | 130 M | 96 M |
Revenue |
- | - | - | - | 2.25 B | 1.87 B | 1.53 B | 1.5 B | 1.42 B | 1.34 B | 1.28 B | 1.34 B | 1.3 B | 1.25 B | 1.17 B |
Cost of Revenue |
- | - | - | - | 801 M | 638 M | 521 M | 501 M | 495 M | 493 M | - | - | - | - | - |
Gross Profit |
1.3 B | 967 M | 1.23 B | 1.38 B | 1.45 B | 1.23 B | 1.01 B | 1 B | 923 M | 845 M | 826 M | 865 M | 815 M | 824 M | 750 M |
Operating Income |
466 M | 97.7 M | 410 M | 531 M | 630 M | 386 M | -26.1 M | 267 M | 153 M | 98.8 M | 179 M | 162 M | 63.3 M | 170 M | 99.6 M |
Interest Expense |
-6.65 M | -739 K | -5.71 M | 6.74 M | 54.5 M | 71.3 M | 74.2 M | 67.3 M | 49.7 M | 39 M | 37.4 M | 39.3 M | 30.9 M | 23.5 M | 25.4 M |
EBITDA |
660 M | 301 M | 615 M | 740 M | 845 M | 591 M | 205 M | 473 M | 370 M | 138 M | 214 M | 198 M | 98.8 M | 206 M | 126 M |
Operating Expenses |
- | - | - | - | 821 M | 695 M | 692 M | 734 M | 769 M | 746 M | 651 M | 704 M | 752 M | 654 M | 650 M |
General and Administrative Expenses |
- | - | - | - | 128 M | 112 M | 112 M | 141 M | 200 M | 129 M | 104 M | 127 M | 199 M | 152 M | 186 M |
All numbers in USD currency
Quarterly Income Statement QIAGEN N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 236 M | - | - | - | 234 M | - | - | - |
All numbers in USD currency
Main types of financial statements QIAGEN N.V. QGENFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting QIAGEN N.V. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Syneos Health
SYNH
|
- | - | $ 4.46 B | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | ||
|
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | ||
|
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | ||
|
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
Bioventus
BVS
|
$ 13.0 | 1.39 % | $ 866 M | ||
|
DarioHealth Corp.
DRIO
|
$ 6.75 | 2.31 % | $ 26.9 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Anixa Biosciences
ANIX
|
$ 2.69 | 1.45 % | $ 87.3 K | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
$ 27.7 | 1.09 % | $ 209 M | ||
|
BioNano Genomics
BNGO
|
$ 1.56 | 17.29 % | $ 8.49 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 11.68 | 0.69 % | $ 123 M | ||
|
CareDx, Inc
CDNA
|
$ 52.64 | 0.52 % | $ 2.81 B | ||
|
Celcuity
CELC
|
$ 82.7 | 0.1 % | $ 3.87 B | ||
|
Co-Diagnostics
CODX
|
$ 1.14 | 2.7 % | $ 1.52 M | ||
|
Charles River Laboratories International
CRL
|
$ 272.88 | 0.59 % | $ 13.5 B | ||
|
Castle Biosciences
CSTL
|
$ 35.5 | 6.16 % | $ 1.03 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 247.08 | 3.9 % | $ 27.4 B | ||
|
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | ||
|
Biomerica
BMRA
|
$ 2.3 | 0.42 % | $ 6.7 M | ||
|
Fulgent Genetics
FLGT
|
$ 21.28 | 3.05 % | $ 655 M | ||
|
Guardant Health
GH
|
$ 175.65 | 4.65 % | $ 22 B | ||
|
ICON Public Limited Company
ICLR
|
$ 172.45 | 2.08 % | $ 13.5 B | ||
|
IDEXX Laboratories
IDXX
|
$ 510.73 | 0.23 % | $ 41.1 B | ||
|
Danaher Corporation
DHR
|
$ 209.36 | 3.01 % | $ 149 B | ||
|
Illumina
ILMN
|
$ 222.29 | 6.76 % | $ 34.5 B | ||
|
IQVIA Holdings
IQV
|
$ 269.67 | 1.51 % | $ 46.4 B | ||
|
Brainsway Ltd.
BWAY
|
$ 13.46 | 0.14 % | $ 457 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 323.97 | 2.75 % | $ 27 B | ||
|
Lantheus Holdings
LNTH
|
$ 100.73 | 0.41 % | $ 6.8 B | ||
|
DexCom
DXCM
|
$ 86.45 | 2.09 % | $ 33.7 B | ||
|
Medpace Holdings
MEDP
|
$ 620.48 | 4.21 % | $ 17.9 B | ||
|
Mettler-Toledo International
MTD
|
$ 1 330.4 | 3.47 % | $ 27.4 B | ||
|
Myriad Genetics
MYGN
|
$ 3.88 | 2.37 % | $ 359 M | ||
|
ENDRA Life Sciences
NDRA
|
$ 5.66 | 1.13 % | $ 4.45 M | ||
|
NeoGenomics
NEO
|
$ 18.89 | 2.61 % | $ 2.42 B | ||
|
Neogen Corporation
NEOG
|
$ 12.25 | 2.51 % | $ 2.66 B | ||
|
National Research Corporation
NRC
|
$ 21.96 | 5.63 % | $ 492 M | ||
|
Natera
NTRA
|
$ 350.78 | 2.63 % | $ 48 B | ||
|
OPKO Health
OPK
|
$ 1.57 | 0.64 % | $ 1.18 B | ||
|
Pacific Biosciences of California
PACB
|
$ 1.34 | 0.37 % | $ 402 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 24.9 | 1.99 % | $ 23.6 B | ||
|
Personalis
PSNL
|
$ 16.1 | 0.31 % | $ 1.44 B |